The California Hospital Association and other partners this week launched , a statewide effort to engage candidates and highlight the importance of addressing behavioral health issues in 2018 elections. 鈥淲e are united behind a powerful cause,鈥  CHA President and CEO and AHA Board Member Carmela Coyle. 鈥淏ehavioral health matters because it affects all of us. Young, old, rich, poor. White, Latino, African-American, Asian. If you鈥檙e diagnosed with cancer, you鈥檙e often surrounded by teams ready to help. But with a behavioral health diagnosis, we often fall into nothingness, without the resources and help and support that鈥檚 needed. That has to change.鈥 Other coalition members include the National Alliance on Mental Illness California, Mental Health America of California, California State Sheriff鈥檚 Association, California State Association of Counties, California Police Chief鈥檚 Association, and Service Employees International Union State Council. According to a recent statewide poll, nearly nine in 10 likely voters want candidates to prioritize behavioral health issues.

Related News Articles

Headline
A new initiative launched March 18 by the Dr. Lorna Breen Heroes' Foundation seeks to improve mental health care access for health care workers. The program,鈥
Headline
A study published Feb. 26 by JAMA Psychiatry found that female physicians died by suicide at more than 1.5 times the rate of female nonphysicians from 2017-鈥
Headline
The Dr. Lorna Breen Heroes鈥 Foundation Feb. 26 recognized 43 licensure boards and 521 hospitals for changing invasive and stigmatizing mental health questions鈥
Headline
The AHA voiced support for bipartisan House legislation introduced Feb. 4 to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act鈥
Headline
In this new 鈥淐aring for Our Kids鈥 episode, David Wagner, pediatric psychologist at Oregon Health and Science University, discusses the Novel Interventions in鈥
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to鈥